Skip to main content
SpringerLink
Log in

The role of nitric oxide in interleukin-2 therapy induced hypotension

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Nitric oxide is an uncharged free radical that mediates a range of physiologic processes in the vasculature. As a principal determinant of vascular tone, the overproduction of nitric oxide has been implicated in the pathogenesis of sepsis- and cytokine-induced hypotension. The enzyme that produces nitric oxide, nitric oxide synthase, exists in three isoforms. One of the three isoforms, inducible nitric oxide synthase, is expressed in many cell types only after stimulation by cytokines and/or endotoxin. Compared to the constitutive nitric oxide synthase enzymes, the inducible enzyme generates larger quantities of nitric oxide for longer periods. Expression of the inducible isoform in vitro requires stimulation by a mixture of cytokines including interferon-γ, tumor necrosis factor-α, and interleukin-1β. These proinflammatory cytokines are known mediators of sepsis and are also produced in the serum of cancer patients during interleukin-2 therapy, thereby leading to excessive production of nitric oxide. Interleukin-2 therapy is associated with a spectrum of cardiovascular toxicities and hemodynamic alterations that are indistinguishable from those seen in septic shock. Many of these hemodynamic effects have been linked to the overproduction of nitric oxide via a cytokine-inducible nitric oxide pathway. In this regard, inhibition of nitric oxide synthesis represents a novel approach to limit the cardiovascular toxicity associated with interleukin-2 therapy and to improve its therapeutic index. Clinical trials to evaluate the efficacy of nitric oxide synthase inhibitors in reversing the hypotension associated with IL-2 therapy are now underway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwartz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169-1188, 1985

    Article  PubMed  Google Scholar 

  2. Talmadge J, Phillips H, Schindler J, Tribble H, Pennington R: Systemic preclinical study on the therapeutic properties of recombinant human interleukin-2 for the treatment of metastatic disease. Cancer Res 47: 5725-5732, 1987

    PubMed  Google Scholar 

  3. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM: Observations on the systemic administration of autologous-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985

    PubMed  Google Scholar 

  4. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A: Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 6: 669-678, 1988

    PubMed  Google Scholar 

  5. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696, 1995

    PubMed  Google Scholar 

  6. Atkins M: Interleukin-2 therapy: a decade of slow but steady progress. Cancer J Sci Am 2: 73-75, 1996

    PubMed  Google Scholar 

  7. Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Corrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA: Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7: 7-20, 1989

    PubMed  Google Scholar 

  8. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JB, Fisher RI, Weiss GR, Doroshaw JH, Jaffe HS, Roper M: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 7: 486-498, 1989

    PubMed  Google Scholar 

  9. Ognibene FP, Rosenberg SA, Skibber J, Shelhamer JH, Lotze MT, Parrillo JE: Interleukin-2 hemodynamics mimic septic shock ‘Abstract’. Clin Res 34: 413, 1986

    Google Scholar 

  10. Blay JY, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR, Philip T: Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res 50: 2371-2374, 1990

    PubMed  Google Scholar 

  11. Kilbourn RG, Belloni P: Endothelial cell production of nitric oxides in responses to interferon ??in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst 82: 772-776, 1990

    PubMed  Google Scholar 

  12. Nathan C, Xie QW: Nitric oxide synthases: roles, tolls, and controls. Cell 78: 915-918, 1994

    Article  PubMed  Google Scholar 

  13. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993

    Article  PubMed  Google Scholar 

  14. Kilbourn RG, Griffith OW: Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 84: 827-831, 1992

    PubMed  Google Scholar 

  15. Beasley D, Schwartz JH, Brenner BM: Interleukin-1induces prolonged L-arginine dependent cyclic guanosine monophosphate in rat vascular smooth muscle. J Clin Invest 87: 602-608, 1991

    PubMed  Google Scholar 

  16. Kilbourn RG, Gross SS, Jubran A, Adams J, Griffith OW, Levi R, Lodato RF: NG-methyl-L-arginine inhibits tumor necrosis factor induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87: 3629-3632, 1990

    PubMed  Google Scholar 

  17. Kilbourn RG, Gross SS, Lodato RF, Adams J, Levi R, Miller LL, Lachman LB, Griffith OW: Inhibition of interleukin-1-a-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-a-induced hypotension by N-omega-amino-L-arginine. J Natl Cancer Inst 84: 1008-1016, 1992

    PubMed  Google Scholar 

  18. Kilbourn RG, Owen-Schaub LB, Cromeens DM, Gross SS, Flaherty MJ, Santee SM, Alak AM, Griffith OW: NG-methyl-L-arginine, an inhibitor of nitric oxide formation reverses interleukin-2 mediated hypotension in dogs. J Appl Physiol 767: 1130-1137, 1994

    Google Scholar 

  19. Hibbs JB Jr., Westenfelder C, Taintor R, Zdenek V, Kablitz C, Baranowski RL, Ward JH, Menlove RL, McMurry MP, Kushner JP, Samlowski WE: Evidence of cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 89: 867-877, 1992

    PubMed  Google Scholar 

  20. Ochoa JB, Curti B, Peitzman AB, Simmons RL, Billiar TR, Hoffman R, Rault R, Longo DL, Urba WJ, Ochoa AC: Increasing circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J Natl Cancer Inst 84: 864-867, 1992

    PubMed  Google Scholar 

  21. Miles D, Thomson F, Balkwil F, Thavasu P, Moncada S: Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with IL-2. Eur J Clin Invest 24: 287-290, 1994

    PubMed  Google Scholar 

  22. Citterio G, Pellegatta F, Di Lucca G, Fragasso G, Scaglietti U, Pini D, Fortis C, Tresoldi M, Rugarli C: Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2. Br J Cancer 74: 1297-1301, 1996

    PubMed  Google Scholar 

  23. Kilbourn RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis CJ: NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med 23: 1018-1024, 1995

    Article  PubMed  Google Scholar 

  24. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, White DE, Steinberg SM, Cole DJ, Kim HI, Levin R, Guleria A, MacFarlane MP, White RL, Einhorn JH, Seipp CA, Rosenberg SA: Randomized comparison of high-dose and low-dose interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 12: 1572-1576, 1994

    PubMed  Google Scholar 

  25. Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Brandon EP, Laird W, Atkins MB: Inhibition of interleukin-2 tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil defect and differential suppression of interleukin-2 associated side—effects. Blood 76: 1933-1940, 1990

    PubMed  Google Scholar 

  26. Du Bois J, Trehu E, Mier J, Shapiro L, Epstein M, Klempner M, Kappler K, Ronayne L, Atkins M: Randomized placebo controlled clinical trial of high-dose interleukin-2 (IL-2) in combination with the soluble TNF receptor IgC chimera (TNFR:Fc) ‘Abstract’. Proc Am Soc Clin Oncol 258: 14, 1995

    Google Scholar 

  27. Margolin K, Atkins M, O’Boyle K, Sosman J, Weiss G, Lotze M, Dutcher J, Fisher R: Prospective randomized trial of lisofylline (LSF) for the modulation of interleukin-2 (IL-2) toxicity ‘Abstract’. Proc Am Soc Clin Oncol 273, 1996

  28. Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A: Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res 54: 3436-3441, 1994

    PubMed  Google Scholar 

  29. Heneka MT, Loschmann PA, Osswald H: Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin-induced shock in the rat. J Clin Invest 99: 47-54, 1997

    PubMed  Google Scholar 

  30. Kilbourn RG, Fonseca G, Price K, Ewer M, Griffith O: Clinical evaluaton of NG-methyl-L-arginine in cancer patients with shock ‘Abstract’ Endothelium 3(suppl): S15, 57, 1995

    Google Scholar 

  31. Papa MZ, Vetto JT, Ettinghausen SE, Mule J, Rosenberg S: Effects of corticosteroids on the antitumor activity of lymphokine activated killer cells and IL-2 in mice. Cancer Res 46: 5618-5623, 1986

    PubMed  Google Scholar 

  32. Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA: Reduction of toxicity of interleukin-2 and lymphokine activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5: 496-503, 1987

    PubMed  Google Scholar 

  33. Forstermann U, Pollock JS, Nakane M: Nitric oxide synthases in the cardiovascular system. Trends Cardiovasc Med 3: 104-110, 1993

    Article  Google Scholar 

  34. Traber DL: Presence and absence of nitric oxide synthase in sepsis. Crit Care Med 24: 1102-1103, 1996

    Article  PubMed  Google Scholar 

  35. MacNaul KL, Hutchinson NI: Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun 196: 1330-1334, 1993

    Article  PubMed  Google Scholar 

  36. Kilbourn R, Owen-Schaub L, Grimm E: Neither lymphokine-activated killer (LAK) cell activity nor tumor necrosis factor mediated tumor cell lysis is altered by inhibitors of nitric oxide synthase ‘Abstract’. Proc Am Assoc Cancer Res 32: 251, 1991

    Google Scholar 

  37. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of a nitric oxide inhibitor in humans with septic shock. Cardiovasc Res 28: 34-39, 1994

    PubMed  Google Scholar 

  38. Kilbourn RG, Szabo C, Traber DL: Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned form experimental and clinical studies. Shock 7: 235-246, 1997

    PubMed  Google Scholar 

  39. Zaccardelli D, Grover R, Colice G: Hemodynamic effects of 546C88 (L-NG-methylarginine (HCL) in an open label, dose escalation study of patients with septic shock. 8th European congress of intensive care medicine. Athens, Greece: October 18-22, 1995

  40. Griffith OW, Park KH, Levi R, Gross SS: The role of plasma arginine in nitric oxide synthesis: Studies with arginasetreated guinea pigs and rats. In: Moncada S, Hibbs J, Higgs EA (eds) The Biology of Nitric Oxide (1) Physiological and Clinical Aspects, Portland Press, London, 1992, pp 6-9

    Google Scholar 

  41. Gross SS, Levi R, Fingert J: Synthesis of tetrahydrobiopterin is a requirement for induction of nitric oxide synthesis by lipopolysaccharide/interferon in vascular smooth muscle. In: Moncada S, Hibbs J, Higgs EA (eds) The Biology of Nitric Oxide (1) Physiological and Clinical Aspects, Portland Press, London, 1992, pp 42-46

    Google Scholar 

  42. Kilbourn RG, DeAngelo J, Bonaventura J: Clinical effects of cell-free hemoglobin, a scavenger of nitric oxide, in septic shock. In: Vincent JL (ed) 1997 Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag, Berlin, 1997, pp 230-239

    Google Scholar 

  43. Fischer SR, Bone HG, Traber DL: Effects of hemoglobin in sepsis. In: Vincent JL (ed) 1997 Yearbook of Intensive Care and E/mergency Medicine. Springer-Verlag, Berlin, 1997, pp 424-441

    Google Scholar 

  44. Rhea G, Bodenham A, Mallick A, Prebelski R, Daily E: Vasopressor effects of diaspirin cross-linked hemoglobin (DCLHb) in critically ill patients ‘Abstract’. Crit Care Med 24: A39, 1996

  45. Phase I study of NG-monomethyl-L-arginine for IL-2-induced hypotension in patients with metastatic melanoma (NCI-95-C-0136). Current Clinical Trials Oncology, National Cancer Institute. PDQ 4: P-499, January/February, 1997

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA

    Homayoun Shahidi & Robert G. Kilbourn

Authors
  1. Homayoun Shahidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert G. Kilbourn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shahidi, H., Kilbourn, R.G. The role of nitric oxide in interleukin-2 therapy induced hypotension. Cancer Metastasis Rev 17, 119–126 (1998). https://doi.org/10.1023/A:1005964907344

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005964907344

Search

Navigation